A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer
Status:
Terminated
Trial end date:
2019-06-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacodynamics, safety and efficacy of PEGPH20
in combination with Avelumab in adult patients with chemotherapy resistant advanced or
locally advanced pancreatic ductal adenocarcinoma (PDAC). This is a multi-center, open-label,
non-randomized trial.